Janssen Collaborates With ViiV Healthcare to Develop Two-Drug Single Tablet Regimen for the Maintenance Treatment of Peo

        
        - Depression or mood changes. Tell your doctor right away if you have any of
          the following symptoms: feeling sad or hopeless, feeling anxious or restless, have
          thoughts of hurting yourself (suicide), or have tried to hurt yourself
        - Liver problems. People with a history of hepatitis B or C virus infection or
          who have certain liver function test changes may have an increased risk of developing
          new or worsening liver problems during treatment. Liver problems were also reported
          during treatment in some people without a history of liver disease. Your healthcare
          professional may need to do tests to check liver function before and during treatment
        - Changes in body shape or body fat have been seen in some patients taking HIV
          medicines. The exact cause and long-term health effects of these conditions are not
          known
        - Changes in your immune system (immune reconstitution syndrome).

Your immune system may get stronger and begin to fight infections. Tell your healthcare professional right away if you start having any new symptoms of infection.

Other common side effects of EDURANT(R) include depression, headache, trouble sleeping (insomnia), and rash.

This is not a complete list of all side effects. If you experience these or other symptoms, contact your healthcare professional right away. Do not stop taking EDURANT(R) or any other medications without first talking to your healthcare professional.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see full Product Information for more details:

http://www.edurant.com/sites/default/files/EDURANT-PI.pdf

About EDURANT(R) (rilpivirine)

Rilpivirine was developed by Janssen R&D Ireland Ltd, one of the Janssen Pharmaceutical Companies.

The registered formulation of rilpivirine is a 25 mg film-coated tablet taken orally once daily. Marketed as EDURANT(R), rilpivirine is indicated, in combination with other ARVs, for the treatment of HIV-1 in ARV treatment-naive adult patients. In most countries, including US and EU, this indication is further restricted to patients with a viral load < 100,000 copies/ mL.

Rilpivirine is available in the United States (US) and the European Union as part of a once daily fixed dose antiretroviral combination with Gilead Sciences Inc's tenofovir and emtricitabine. This combination, known as COMPLERA(R) (US) or EVIPLERA(R), was granted marketing authorisation from the Food and Drug Administration in August 2011, with Gilead Sciences Inc being the marketing authorisation holder in the US, and from the European Commission in November 2011, with Gilead Sciences International Ltd. being the marketing authorisation holder in Europe, Middle East and Africa.

About TIVICAY(R) (dolutegravir)

TIVICAY(R) (dolutegravir) is an integrase inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 in adults and children aged 12 years and older weighing at least 40 kg. Integrase inhibitors block HIV replication by preventing the viral DNA from integrating into the genetic material of human immune cells (T-cells). This step is essential in the HIV replication cycle and is also responsible for establishing chronic infection. It is available as a small, yellow, 50 mg tablet. Importantly, it can be taken with or without food and at any time of the day.

About Janssen

At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in infectious diseases and vaccines, oncology, immunology, neuroscience, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen R&D Ireland Ltd, any of the Janssen Pharmaceutical Companies and/or Johnson & Johnson.

Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; changes to governmental laws and regulations and domestic and foreign health care reforms; general industry conditions including trends toward health care cost containment; and increased scrutiny of the health care industry by government agencies.

A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2013, including in Exhibit 99 thereto, and our subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at http://www.sec.gov, http://www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statements as a result of new information or future events or developments.)

1. World Health Organization. Global summary of the AIDS epidemic. Available at: http://www.who.int/gho/hiv/en/ [http://www.who.int/gho/hiv/en ]. Last accessed June 2014.

2. Hui Dy. Effects of HIV protease inhibitor therapy on lipid metabolism. Prog Lipid Res 2003; http://www.ncbi.nlm.nih.gov/pubmed/12547... 42(2):81-92.

3. World Health Organization. Global summary of the AIDS epidemic. Available at: http://www.who.int/hiv/data/2012_epi_cor.... Last accessed June 2014.

        
        MEDIA CONTACT:
        Ronan Collins
        +47-488-42500
        rcollin5@its.jnj.com

        INVESTOR RELATIONS:
        Stan Panasewicz
        +1-732-524-2524

        Louise Mehrotra
        +1-732-524-6491